Clinuvel posts FY2026 net profit after tax of A$34 million, cash reserves rise to A$252 million

• Clinuvel posted FY2026 revenue of A$64 million, down 1%, with net profit after tax of A$34 million, down 6%.
• Total revenue including interest and other income reached A$101 million, down 4%.
• Cash reserves rose 12% to A$252 million, with net tangible assets backing per share at A$5.35, up 12%.
• Expenses totaled A$53 million, down 0.5%, with R&D at 34% of spending.
• Dividend held at A$0.05 per share, with basic earnings per share of A$0.68, down 6%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.